Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Eribulin (Primary) ; Everolimus (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
- 09 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 02 Oct 2014 Planned initiation date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.